

counsel for Ranbaxy provided a complete inventory of PAREXEL audit work. Counsel has indicated that Ranbaxy will continue to assert opinion work product privilege, but the scope and basis for those claims must await further production and preparation of privilege logs. Nonetheless, efforts are underway to comply with the subpoena.

In consideration of the current pace and apparent agreement to produce the PAREXEL documents, the United States respectfully requests that the Court hold the Motion in abeyance for a reasonable period of time to allow Ranbaxy and PAREXEL to produce the audit documents and to allow the government to confirm that all documents have been produced and to review Ranbaxy's privilege log for claims of opinion work product. The government intends to withdraw the Motion upon full and complete production of the PAREXEL documents.

Respectfully submitted,

Rod J. Rosenstein
United States Attorney

By: _____/s/_____
Roann Nichols
Assistant United States Attorney
36 S. Charles Street, Fourth Floor
Baltimore, Maryland 21201
410-209-4800

By: _____/s/_____
Michele Sartori
Assistant United States Attorney
400 United States Courthouse
6500 Cherrywood Lane
Greenbelt, Maryland 20770-1249
301-344-4433

/s/

Linda I. Marks
Senior Litigation Counsel
U.S. Department of Justice
Office of Consumer Litigation
P.O. Box 386
Washington, D.C. 20044
202-307-0060